BR112013033831A2 - composição farmacêutica oftalmológica tópica que contém regorafenib - Google Patents

composição farmacêutica oftalmológica tópica que contém regorafenib

Info

Publication number
BR112013033831A2
BR112013033831A2 BR112013033831A BR112013033831A BR112013033831A2 BR 112013033831 A2 BR112013033831 A2 BR 112013033831A2 BR 112013033831 A BR112013033831 A BR 112013033831A BR 112013033831 A BR112013033831 A BR 112013033831A BR 112013033831 A2 BR112013033831 A2 BR 112013033831A2
Authority
BR
Brazil
Prior art keywords
topical ophthalmic
ophthalmic pharmaceutical
composition containing
pharmaceutical composition
regorafenib
Prior art date
Application number
BR112013033831A
Other languages
English (en)
Inventor
Richter Annett
Ohm Andreas
Riedl Bernd
Hirth-Dietrich Claudia
Von Degenfeld Georges
Keldenich Joerg
Freundlieb Julia
Klar Jürgen
Böttger Michael
Muenster Uwe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013033831(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BR112013033831A2 publication Critical patent/BR112013033831A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo da patente de invenção para: “composição farmacêutica oftalmológica tópica que contém regorafenib”. a presente invenção refere-se a composições farmacêuticas oftalmológicas tópicas que contêm regorafenib, um hidrato, solvato ou sal farmaceuticamente aceitável do mesmo ou um polimorfo do mesmo e seu processo de preparação e sua utilização para tratamento de doenças oculares.
BR112013033831A 2011-06-28 2012-06-26 composição farmacêutica oftalmológica tópica que contém regorafenib BR112013033831A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14
PCT/EP2012/062365 WO2013000917A1 (en) 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib

Publications (1)

Publication Number Publication Date
BR112013033831A2 true BR112013033831A2 (pt) 2017-02-14

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033831A BR112013033831A2 (pt) 2011-06-28 2012-06-26 composição farmacêutica oftalmológica tópica que contém regorafenib

Country Status (25)

Country Link
US (1) US20140296301A1 (pt)
EP (1) EP2726059A1 (pt)
JP (1) JP5998213B2 (pt)
KR (1) KR20140048218A (pt)
CN (1) CN103889399A (pt)
AP (1) AP2013007335A0 (pt)
AR (1) AR086800A1 (pt)
AU (1) AU2012277905A1 (pt)
BR (1) BR112013033831A2 (pt)
CA (1) CA2840329A1 (pt)
CL (1) CL2013003700A1 (pt)
CO (1) CO6920289A2 (pt)
CR (1) CR20130693A (pt)
CU (1) CU24163B1 (pt)
DO (1) DOP2013000314A (pt)
EA (1) EA201400064A1 (pt)
EC (1) ECSP13013106A (pt)
GT (1) GT201300322A (pt)
HK (1) HK1197176A1 (pt)
MX (1) MX2013015287A (pt)
PE (1) PE20141031A1 (pt)
TN (1) TN2013000533A1 (pt)
UY (1) UY34166A (pt)
WO (1) WO2013000917A1 (pt)
ZA (1) ZA201400646B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0515946A (pt) 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
MX2017015838A (es) * 2015-06-06 2018-08-15 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
ATE417628T1 (de) * 2002-05-28 2009-01-15 Nycomed Gmbh Topisch anwendbare pharmazeutische zubereitung
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
KR20080011310A (ko) 2005-05-10 2008-02-01 알콘, 인코퍼레이티드 폴록사머 또는 메록사폴 계면활성제 및 글리콜을유효성분으로 함유하는 현탁제, 안질환 치료용 의약의제조를 위한 그의 용도
JP2008543775A (ja) 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
PT1968594E (pt) 2005-11-29 2010-11-18 Glaxosmithkline Llc Tratamento de distúrbios neovasculares oculares tais como degeneração macular, estrias angióides, uveite e edema macular
JP2009519267A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
CA2760687A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
WO2011009016A1 (en) 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method

Also Published As

Publication number Publication date
CU20130168A7 (es) 2014-04-24
EA201400064A1 (ru) 2014-05-30
UY34166A (es) 2013-01-31
CU24163B1 (es) 2016-03-31
CN103889399A (zh) 2014-06-25
CR20130693A (es) 2016-05-02
JP2014518233A (ja) 2014-07-28
HK1197176A1 (en) 2015-01-09
AP2013007335A0 (en) 2013-12-31
CO6920289A2 (es) 2014-04-10
NZ619229A (en) 2016-04-29
CL2013003700A1 (es) 2014-07-18
GT201300322A (es) 2014-11-13
TN2013000533A1 (en) 2015-03-30
US20140296301A1 (en) 2014-10-02
AR086800A1 (es) 2014-01-22
EP2726059A1 (en) 2014-05-07
ZA201400646B (en) 2015-11-25
WO2013000917A1 (en) 2013-01-03
KR20140048218A (ko) 2014-04-23
CA2840329A1 (en) 2013-01-03
PE20141031A1 (es) 2014-08-21
MX2013015287A (es) 2014-03-31
AU2012277905A1 (en) 2014-01-16
JP5998213B2 (ja) 2016-09-28
ECSP13013106A (es) 2014-01-31
DOP2013000314A (es) 2014-04-15
AU2012277905A8 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112014015845A8 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
EP3653205A3 (en) Oxymethazoline for topical ophthalmic administration and uses thereof
BR112015007647A2 (pt) derivados de quetamina
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
BR112014004435A2 (pt) inibidores de quinase rock
BR112015019919A2 (pt) compostos bicíclicos
BR112014004732A2 (pt) composto benzotiazolona
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
ECSP15026386A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112015006243A2 (pt) agentes antibacterianos de fenicol
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
BR112013029146A2 (pt) composto, composição farmacêutica, e, kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]